EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Omalizumab Dose‐Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study

Stefania Arasi iD, Carol Bitetti iD, Lucia Lo Scalzo iD, Alessandra Spagnoli iD, Elena Fabrizi iD, Alessandro Fiocchi iD, Arianna Cafarotti iD

Allergy · 2026-04 · 81 (4) · 1239-1246

DOI: 10.1111/all.70228 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Allergy, online erschienen am 19.01.2026. Verfasst von Stefania Arasi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Omalizumab, Food Hypersensitivity, Anti-Allergic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Allegria ONLUS, Milano, Italy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We recently published on the clinical efficacy of a 1‐year‐long evaluation of 65 asthmatics with severe IgE‐mediated food allergy (FA) under Omalizumab: Omalizumab is safe and able to increase reactivity threshold, allows safe food introduction, and improves quality of life (OSAFA‐study, ClinicalTrials.gov , NCT06316414). Herein, we assess Omalizumab dose–related efficacy during the first year Omalizumab treatment in achieving food desensitization in patients with severe FA.

Methods

Children (6–18 years) with severe asthma and severe allergy to ≥ 1 food allergen were screened. Oral food challenges (OFCs), skin prick test (SPT), complete blood count, chemistry, total and specific IgE were measured at baseline and at 12 months of Omalizumab.

Results

Seventy‐six patients (previously published cohort plus 11 newly‐enrolled patients) were included (OSAFA [Omalizumab in Severe Asthmatics with Food Allergy] study). 69.7% were male; mean age (SD) 12.2 [4.19] years. 77.6% were allergic to 2+ foods. Total IgE median was 644 kU/L. After adjusting for confounders, such as age, sex, and co‐existing allergies, a significant association was observed between the achievement of desensitization and the dosage (mg/month) of Omalizumab (OR: 1.151, 95% CI: 1.066–1.258), while no significant effect was observed for total IgE levels at the baseline (OR: 0.999, 95% CI: 0.998–1.001).

Conclusions

The findings of this study indicate that the efficacy of Omalizumab is independent, all else being equal, from total IgE levels, suggesting that body weight is the most appropriate parameter for calculating its dosage in the treatment of patients with severe FA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabFood HypersensitivityAnti-Allergic AgentsHumansChildMaleFemaleAdolescentImmunoglobulin ETreatment OutcomeSeverity of Illness IndexAllergensDose-Response Relationship, DrugSkin TestsCohort Studies

Stichwörter der Autor:innen

anti‐IgEchildrenfood allergyomalizumabomalizumab dosage

Substanzen

OmalizumabImmunoglobulin EAnti-Allergic AgentsAllergens

Autor:innen und Institutionen

  • Allergy Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Department of Paediatrics, San Carlo Hospital, Potenza, Italy.
  • Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Department of Political Science, University of Teramo, Teramo, Italy.

ORCID-Profile: Stefania Arasi, Carol Bitetti, Lucia Lo Scalzo, Alessandra Spagnoli, Elena Fabrizi, Alessandro Fiocchi, Arianna Cafarotti

Förderung

  • Allegria ONLUS, Milano, Italy

Zitieren

APA

Arasi, S., Bitetti, C., Lo Scalzo, L., Spagnoli, A., Fabrizi, E., Fiocchi, A., & Cafarotti, A. (2026). Omalizumab Dose‐Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study. Allergy, 81(4), 1239-1246. https://doi.org/10.1111/all.70228

Vancouver

Arasi S, Bitetti C, Lo Scalzo L, Spagnoli A, Fabrizi E, Fiocchi A, et al. Omalizumab Dose‐Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study. Allergy. 2026;81(4):1239-1246. doi:10.1111/all.70228

BibTeX
@article{Arasi2026,
  author = {Arasi, Stefania and Bitetti, Carol and Lo Scalzo, Lucia and Spagnoli, Alessandra and Fabrizi, Elena and Fiocchi, Alessandro and Cafarotti, Arianna},
  title = {Omalizumab Dose‐Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {4},
  pages = {1239--1246},
  doi = {10.1111/all.70228}
}
Kostenlos starten →